Zoetis Inc. $ZTS Shares Sold by Fieldview Capital Management LLC

Fieldview Capital Management LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 49.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,039 shares of the company’s stock after selling 9,655 shares during the period. Fieldview Capital Management LLC’s holdings in Zoetis were worth $1,469,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC raised its stake in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the period. Financial Consulate Inc. acquired a new position in Zoetis during the 3rd quarter valued at approximately $39,000. SJS Investment Consulting Inc. grew its stake in Zoetis by 1,606.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after buying an additional 257 shares during the last quarter. TruNorth Capital Management LLC bought a new stake in Zoetis in the third quarter valued at $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Zoetis during the third quarter valued at $46,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $122.29 on Tuesday. The stock has a fifty day moving average price of $125.99 and a two-hundred day moving average price of $132.65. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The firm has a market cap of $51.62 billion, a P/E ratio of 20.31, a PEG ratio of 1.85 and a beta of 0.95. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.00.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. HSBC set a $140.00 target price on shares of Zoetis in a research report on Wednesday, December 10th. Morgan Stanley set a $160.00 price target on Zoetis in a research report on Thursday, December 18th. Stifel Nicolaus cut their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Barclays began coverage on shares of Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.